PL4000615T3 - Podwójne antagonisty tnfr1 i agonisty tnfr2 do stosowania w chorobach nerek - Google Patents

Podwójne antagonisty tnfr1 i agonisty tnfr2 do stosowania w chorobach nerek

Info

Publication number
PL4000615T3
PL4000615T3 PL20207534.7T PL20207534T PL4000615T3 PL 4000615 T3 PL4000615 T3 PL 4000615T3 PL 20207534 T PL20207534 T PL 20207534T PL 4000615 T3 PL4000615 T3 PL 4000615T3
Authority
PL
Poland
Prior art keywords
dual
renal diseases
tnfr2 agonists
tnfr1 antagonists
tnfr1
Prior art date
Application number
PL20207534.7T
Other languages
English (en)
Inventor
Eva Steiness
Torben Frank SKARSFELDT
Original Assignee
Serodus Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serodus Asa filed Critical Serodus Asa
Publication of PL4000615T3 publication Critical patent/PL4000615T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL20207534.7T 2020-11-13 2020-11-13 Podwójne antagonisty tnfr1 i agonisty tnfr2 do stosowania w chorobach nerek PL4000615T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20207534.7A EP4000615B1 (en) 2020-11-13 2020-11-13 Dual tnfr1 antagonists and tnfr2 agonists for use in renal diseases

Publications (1)

Publication Number Publication Date
PL4000615T3 true PL4000615T3 (pl) 2022-12-19

Family

ID=73448924

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20207534.7T PL4000615T3 (pl) 2020-11-13 2020-11-13 Podwójne antagonisty tnfr1 i agonisty tnfr2 do stosowania w chorobach nerek

Country Status (9)

Country Link
US (1) US12083097B2 (pl)
EP (1) EP4000615B1 (pl)
JP (1) JP7462116B2 (pl)
CN (1) CN116568296A (pl)
AU (1) AU2021378077B2 (pl)
CA (1) CA3197986A1 (pl)
ES (1) ES2930093T3 (pl)
PL (1) PL4000615T3 (pl)
WO (1) WO2022101389A1 (pl)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1976509T3 (pl) 2006-01-18 2015-07-31 Evolva Sa Modulatory PPAR
US8486994B2 (en) * 2007-01-18 2013-07-16 Evolva Sa Prodrugs of substituted 1,3-dioxanes and their uses
EP2120567A4 (en) * 2007-01-18 2011-11-09 Evolva Sa PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES
JP2016504994A (ja) * 2012-12-18 2016-02-18 エヴォルヴァ エスアー 糖尿病患者における心血管リスクの治療
WO2015193630A1 (en) * 2014-06-18 2015-12-23 Evolva Sa Treatment of cardiovascular risk in patients with cardiovascular disease and/or diabetes
CN111825547B (zh) * 2019-04-23 2022-04-19 南京海融医药科技股份有限公司 一种芳基丙酸类化合物的盐及其制药用途

Also Published As

Publication number Publication date
ES2930093T3 (es) 2022-12-07
US20230414562A1 (en) 2023-12-28
WO2022101389A1 (en) 2022-05-19
AU2021378077B2 (en) 2024-03-14
EP4000615B1 (en) 2022-10-19
JP2023554588A (ja) 2023-12-28
CN116568296A (zh) 2023-08-08
CA3197986A1 (en) 2022-05-19
JP7462116B2 (ja) 2024-04-04
AU2021378077A1 (en) 2023-05-25
US12083097B2 (en) 2024-09-10
EP4000615A1 (en) 2022-05-25

Similar Documents

Publication Publication Date Title
SI3806955T1 (sl) Agonisti receptorja glp-1 in njihova uporaba
IL200572A0 (en) Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
ZA202206885B (en) Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof
IL285289A (en) Devices and methods for bodily fluid collection and distribution
IL279015A (en) Anti-interleukin-17A antibody, its pharmaceutical preparation and its use
IL198829A0 (en) Gm-csf antagonist use in treating chronic inflammatory diseases
SG10202006451QA (en) Managing transactions in multiple blockchain networks
EP2948544A4 (en) CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
CL2013002869A1 (es) Una combinacion que contiene 2-amino-n-[7-metoxi-8-(3-morfolin-4-ilpropoxi)-2,3-dihidroimidazo[1,2-c]quinazolin-5-il]pirimidin-5-carboxamida y abt-737; y su uso para el tratamiento o profilaxis de cancer de mama, en particular cáncer de mama inflamatorio, cancer de mama triple negativo, cancer de mama positivo a receptor de her2 y cancer de mama positivo a receptor de hormona.
PL4025592T3 (pl) Sprzężone mimetyki hepcydyny do stosowania w leczeniu czerwienicy prawdziwej
EP3617224A4 (en) SN 10 SELECTIVE ANTAGONIST OF TNFR1 AND ITS USE TO TREAT INFLAMMATORY DISEASE OF THE INTESTINE
PL3806898T3 (pl) Antagonista gremlin-1 do zastosowania w leczeniu nowotworu
IL199045A0 (en) Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
IL283104A (en) Antagonistic cd40 monoclonal antibodies and uses thereof
EP3062818A4 (en) Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
SG11201911599XA (en) Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
IL277634A (en) Leptin receptor agonist antibody for use in the treatment of metabolic dysfunction or hypoleptinemia
SG11202010521VA (en) Use of neutrophil elastase inhibitors in liver disease
CL2011002416A1 (es) Uso de un anticuerpo anti-il 17a y/o il-17f o fragmento que une antígeno del mismo que sirve en la preparación de un medicamento para el tratamiento de un trastorno de resistencia a insulina en un mamifero; kit.
DOP2016000003A (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán
SG11202101435XA (en) ANTIBODY AGAINST IL-1ß, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP4054597A4 (en) BLOOD PLASMA FRACTIONS FOR USE IN MUSCLE REGENERATION
HRP20220346T3 (hr) Antagonist glp-1 receptora za upotrebu u liječenju kongenitalnog hiperinzulinizma
PL4000615T3 (pl) Podwójne antagonisty tnfr1 i agonisty tnfr2 do stosowania w chorobach nerek
TWI799398B (zh) 供用於多層結構中之聚合物摻合物及包含所述聚合物摻合物之多層結構